Does the media refer more to VRDN or MDXG?

In the previous week, Viridian Therapeutics had 5 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for Viridian Therapeutics and 2 mentions for MiMedx Group. Viridian Therapeutics' average media sentiment score of 1.41 beat MiMedx Group's score of 0.84 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RARE or MDXG?

In the previous week, Ultragenyx Pharmaceutical had 80 more articles in the media than MiMedx Group. MarketBeat recorded 82 mentions for Ultragenyx Pharmaceutical and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.84 beat Ultragenyx Pharmaceutical's score of -0.25 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 10 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 33 Negative mention(s) 2 Very Negative mention(s) Neutral MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MDXG or CDNA?

MiMedx Group has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.59 $48.58M $0.04 114.25 CareDx $379.80M 6.93 -$21.35M $2.07 24.58

Is MDXG or CDNA more profitable?

CareDx has a net margin of 24.23% compared to MiMedx Group's net margin of 1.76%. MiMedx Group's return on equity of 12.09% beat CareDx's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% CareDx 24.23% 2.87% 2.17%

Does the media prefer MDXG or CDNA?

In the previous week, CareDx had 9 more articles in the media than MiMedx Group. MarketBeat recorded 11 mentions for CareDx and 2 mentions for MiMedx Group. CareDx's average media sentiment score of 1.11 beat MiMedx Group's score of 0.84 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDXG or BCRX?

In the previous week, BioCryst Pharmaceuticals had 8 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for BioCryst Pharmaceuticals and 2 mentions for MiMedx Group. BioCryst Pharmaceuticals' average media sentiment score of 1.39 beat MiMedx Group's score of 0.84 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MDXG or PGEN?

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.59 $48.58M $0.04 114.25 Precigen $85.72M 29.53 -$250.64M -$1.04 N/A

Is MDXG or PGEN more profitable?

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% Precigen -183.98% 423.75% 84.39%

Does the media prefer MDXG or PGEN?

In the previous week, MiMedx Group and MiMedx Group both had 2 articles in the media. Precigen's average media sentiment score of 1.75 beat MiMedx Group's score of 0.84 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

MiMedx Group (MDXG) Competitors

$4.57 +0.14 (+3.16%)

As of 09/4/2026 04:00 PM Eastern

Compare

MDXG vs. VRDN, RARE, CDNA, BCRX, and PGEN

Should you buy MiMedx Group stock or one of its competitors? MiMedx Group's main competitors and comparable companies include Viridian Therapeutics (VRDN), Ultragenyx Pharmaceutical (RARE), CareDx (CDNA), BioCryst Pharmaceuticals (BCRX), and Precigen (PGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MiMedx Group compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

79.2% of MiMedx Group shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viridian Therapeutics currently has a consensus target price of $38.54, indicating a potential upside of 68.14%. MiMedx Group has a consensus target price of $8.57, indicating a potential upside of 87.56%. Given MiMedx Group's higher possible upside, analysts plainly believe MiMedx Group is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Viridian Therapeutics had 5 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for Viridian Therapeutics and 2 mentions for MiMedx Group. Viridian Therapeutics' average media sentiment score of 1.41 beat MiMedx Group's score of 0.84 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	36.65	-$342.60M	-$3.37	N/A
MiMedx Group	$418.63M	1.59	$48.58M	$0.04	114.25

Viridian Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

MiMedx Group has a net margin of 1.76% compared to Viridian Therapeutics' net margin of -505.86%. MiMedx Group's return on equity of 12.09% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
MiMedx Group	1.76%	12.09%	9.22%

Summary

MiMedx Group beats Viridian Therapeutics on 11 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 80 more articles in the media than MiMedx Group. MarketBeat recorded 82 mentions for Ultragenyx Pharmaceutical and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.84 beat Ultragenyx Pharmaceutical's score of -0.25 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	10 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	33 Negative mention(s)	2 Very Negative mention(s)	Neutral
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.24	-$575M	-$5.84	N/A
MiMedx Group	$418.63M	1.59	$48.58M	$0.04	114.25

Ultragenyx Pharmaceutical currently has a consensus target price of $36.63, suggesting a potential upside of 139.42%. MiMedx Group has a consensus target price of $8.57, suggesting a potential upside of 87.56%. Given Ultragenyx Pharmaceutical's higher possible upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 1.76% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. MiMedx Group's return on equity of 12.09% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
MiMedx Group	1.76%	12.09%	9.22%

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to CareDx?

MiMedx Group (NASDAQ:MDXG) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, CareDx had 9 more articles in the media than MiMedx Group. MarketBeat recorded 11 mentions for CareDx and 2 mentions for MiMedx Group. CareDx's average media sentiment score of 1.11 beat MiMedx Group's score of 0.84 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.59	$48.58M	$0.04	114.25
CareDx	$379.80M	6.93	-$21.35M	$2.07	24.58

79.2% of MiMedx Group shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 2.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CareDx has a net margin of 24.23% compared to MiMedx Group's net margin of 1.76%. MiMedx Group's return on equity of 12.09% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
CareDx	24.23%	2.87%	2.17%

MiMedx Group has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

MiMedx Group presently has a consensus target price of $8.57, suggesting a potential upside of 87.56%. CareDx has a consensus target price of $51.20, suggesting a potential upside of 0.63%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

MiMedx Group beats CareDx on 10 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to BioCryst Pharmaceuticals?

MiMedx Group (NASDAQ:MDXG) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, BioCryst Pharmaceuticals had 8 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for BioCryst Pharmaceuticals and 2 mentions for MiMedx Group. BioCryst Pharmaceuticals' average media sentiment score of 1.39 beat MiMedx Group's score of 0.84 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MiMedx Group currently has a consensus price target of $8.57, indicating a potential upside of 87.56%. BioCryst Pharmaceuticals has a consensus price target of $20.60, indicating a potential upside of 106.83%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

MiMedx Group has a net margin of 1.76% compared to BioCryst Pharmaceuticals' net margin of -40.90%. MiMedx Group's return on equity of 12.09% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

MiMedx Group has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than MiMedx Group. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.59	$48.58M	$0.04	114.25
BioCryst Pharmaceuticals	$874.84M	2.91	$263.86M	-$1.50	N/A

Summary

BioCryst Pharmaceuticals beats MiMedx Group on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Precigen?

MiMedx Group (NASDAQ:MDXG) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Precigen	-183.98%	423.75%	84.39%

MiMedx Group currently has a consensus target price of $8.57, suggesting a potential upside of 87.56%. Precigen has a consensus target price of $14.50, suggesting a potential upside of 104.23%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

MiMedx Group has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.59	$48.58M	$0.04	114.25
Precigen	$85.72M	29.53	-$250.64M	-$1.04	N/A

In the previous week, MiMedx Group and MiMedx Group both had 2 articles in the media. Precigen's average media sentiment score of 1.75 beat MiMedx Group's score of 0.84 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

MiMedx Group and Precigen tied by winning 8 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$666.12M	$4.00B	$7.24B	$12.91B
Dividend Yield	N/A	3.60%	2.53%	9.14%
P/E Ratio	114.28	12.77	274.10	25.45
Price / Sales	1.59	1,399.63	687.92	126.65
Price / Cash	8.25	108.60	77.08	52.44
Price / Book	3.09	16.14	12.85	6.17
Net Income	$48.58M	-$22.80M	$3.49B	$350.08M
7 Day Performance	1.56%	0.31%	1.04%	-0.14%
1 Month Performance	9.33%	7.97%	5.39%	0.94%
1 Year Performance	-35.99%	49.26%	24.18%	14.02%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	2.4979 of 5 stars	$4.57 +3.2%	$8.57 +87.6%	-36.0%	$666.12M	$418.63M	114.28	870
VRDN Viridian Therapeutics	3.6303 of 5 stars	$23.07 -0.4%	$38.54 +67.0%	+22.4%	$2.61B	$70.85M	N/A	50	Positive News
RARE Ultragenyx Pharmaceutical	2.7934 of 5 stars	$25.74 +2.1%	$59.44 +131.0%	-51.9%	$2.54B	$673M	N/A	1,371	Trending News Analyst Downgrade Options Volume Gap Up
CDNA CareDx	3.3525 of 5 stars	$48.82 -2.6%	$47.75 -2.2%	+268.2%	$2.53B	$379.80M	23.60	740	News Coverage Positive News Analyst Forecast
BCRX BioCryst Pharmaceuticals	2.9423 of 5 stars	$9.89 +2.0%	$20.60 +108.2%	+20.4%	$2.53B	$940.61M	N/A	530	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. VRDN, RARE, CDNA, BCRX, and PGEN

How does MiMedx Group compare to Viridian Therapeutics?

Summary

How does MiMedx Group compare to Ultragenyx Pharmaceutical?

Summary

How does MiMedx Group compare to CareDx?

Summary

How does MiMedx Group compare to BioCryst Pharmaceuticals?

Summary

How does MiMedx Group compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. VRDN, RARE, CDNA, BCRX, and PGEN

How does MiMedx Group compare to Viridian Therapeutics?

Do insiders and institutionals believe in VRDN or MDXG?

Do analysts recommend VRDN or MDXG?

Does the media refer more to VRDN or MDXG?

Which has stronger valuation and earnings, VRDN or MDXG?

Which has more volatility & risk, VRDN or MDXG?

Is VRDN or MDXG more profitable?

Summary

How does MiMedx Group compare to Ultragenyx Pharmaceutical?

Which has more risk & volatility, RARE or MDXG?

Does the media favor RARE or MDXG?

Which has stronger earnings and valuation, RARE or MDXG?

Do analysts recommend RARE or MDXG?

Is RARE or MDXG more profitable?

Do institutionals and insiders have more ownership in RARE or MDXG?

Summary

How does MiMedx Group compare to CareDx?

Does the media prefer MDXG or CDNA?

Which has stronger valuation & earnings, MDXG or CDNA?

Do insiders & institutionals hold more shares of MDXG or CDNA?

Is MDXG or CDNA more profitable?

Which has more risk and volatility, MDXG or CDNA?

Do analysts prefer MDXG or CDNA?

Summary

How does MiMedx Group compare to BioCryst Pharmaceuticals?

Does the media prefer MDXG or BCRX?

Do insiders and institutionals believe in MDXG or BCRX?

Do analysts prefer MDXG or BCRX?

Is MDXG or BCRX more profitable?

Which has more risk & volatility, MDXG or BCRX?

Which has higher valuation & earnings, MDXG or BCRX?

Summary

How does MiMedx Group compare to Precigen?

Do institutionals and insiders have more ownership in MDXG or PGEN?

Is MDXG or PGEN more profitable?

Do analysts rate MDXG or PGEN?

Which has more volatility and risk, MDXG or PGEN?

Which has better valuation and earnings, MDXG or PGEN?

Does the media prefer MDXG or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools